Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18

Massimo Gadina, Silvana Canevari, Marina Ripamonti, Massimo Mariani, Maria Ines Colnaghi

Research output: Contribution to journalArticlepeer-review

Abstract

The in vivo behavior of the monoclonal antibody (MAb) MOv18, with a restricted specificity for human ovarian carcinoma was analyzed on normal and tumor-bearing animals. The pharmacokinetics of the iodine-labeled MAb carried out in BALB/c mice fits an open two-compartment model. The t 1 2 alpha was found not to be influenced by the different iodine isotopes used (125I vs 131I) and by the time between labeling procedures and administration. The t 1 2 beta were found to be longer after i.p. than i.v. administration and influenced by the time lapse between preparation and administration. A radiolocalization study was carried out in CD1 nu/nu mice bearing i.p. xenotransplant of the human ovarian carcinoma cell line IGROV1. Tumor/non tumor ratios were higher when the time between administration and sacrifice was short and, for 131I-MOv18, with a short interval between labeling and injection. Even if longer half lives were obtained using 125I-MOv18 and i.p. administration a fairly rapid decrease in the values of the percentage of the injected dose per gram of tumor during the time was noted. These data indicate that this MAb could be considered a good candidate for radiotherapeutic approaches.

Original languageEnglish
Pages (from-to)403-408
Number of pages6
JournalInternational Journal of Radiation Applications and Instrumentation.
Volume18
Issue number4
DOIs
Publication statusPublished - 1991

Fingerprint Dive into the research topics of 'Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18'. Together they form a unique fingerprint.

Cite this